About 30 results found for searched term "Ferroptosis" (0.172 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2197 | Sulfasalazine | Ferroptosis |
| Salazopyrin；Azulfidine；Sulphasalazine; SAS | ||
| Sulfasalazine is a sulfonamide agent derived from Mesalazine. Sulfasalazine has xC-system inhibitory activity associated with iron death and is primarily used as an anti-inflammatory agent. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer. | ||
| M2679 | Erastin | Ferroptosis |
| Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M2698 | Ferrostatin-1 | Ferroptosis |
| Fer-1 | ||
| Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis with EC50 of 60 nM. | ||
| M3497 | Simvastatin (MK 733) | Autophagy |
| MK 733; MK-0733 | ||
| Simvastatin (MK-0733, MK 733) is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis. Simvastatin inhibits exosome release. Prior to use in cell assays, Simvastatin needs to be activated by NaOH in EtOH treatment. | ||
| M7434 | Trolox | ROS |
| Trolox is a vitamin E analogue that has powerful antioxidant properties. Trolox is a scavenger of ROS. Trolox is also a ferroptosis inhibitor. | ||
| M7504 | CIL56 (CA3) | Ferroptosis |
| CIL56 (CA3) is a potent and selective ferroptosis inducer, it has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. | ||
| M8531 | Liproxstatin-1 | Ferroptosis |
| Lip-1 | ||
| Liproxstatin-1 is a potent inhibitor of ferroptosis, a non-apoptotic form of cell death characterized by iron-dependent accumulation of lethal lipid reactive oxygen species (ROS). | ||
| M9060 | RSL3 | Ferroptosis |
| 1S,3R-RSL3 | ||
| RSL3 is an inhibitor of the glutathione (GSH) peroxidase 4, and a ferroptosis activator, which can inhibit the cysteine/glutamate amino acid transporter system. | ||
| M9404 | UAMC-3203 hydrochloride | Ferroptosis |
| UAMC-3203 HCl | ||
| UAMC-3203 hydrochloride is a potent and selective Ferroptosis inhibitor, with an IC50 of 12 nM. | ||
| M10586 | JKE-1674 | Ferroptosis |
| JKE1674 | ||
| JKE-1674 is an inhibitor of glutathione peroxidase 4 (GPX4) and an active metabolite of the GPX4 inhibitor ML-210. JKE-1674 reduces viability of LOX-IMVI cancer cells and in a panel of additional cancer cell lines, an effect that can be blocked by the ferroptosis inhibitor ferrostatin-1. | ||
| M10626 | UAMC-3203 | Ferroptosis |
| UAMC3203 | ||
| UAMC-3203 is an improved ferroptosis inhibitor, with an IC50 value of 10 nM in IMR-32 neuroblastoma cells. | ||
| M11044 | SRS16-86 | Ferroptosis |
| SRS16-86 is a potent inhibitor of ferroptosis. SRS16-86 is more metabolically and plasma-stable in vivo than Ferrostatin-1. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) studies. | ||
| M11314 | iFSP1 | Ferroptosis |
| IFSP1 is an effective, selective and glutathione-independent inhibitor of ferroptosis Suppressor protein 1 (FSP1/AIFM2) with an EC50 value of 103 nM. IFSP1 can selectively induce iron death in Pfa1 cells and HT1080 cells with GPX4 knockout gene overexpressing FSP1. | ||
| M11328 | FINO2 | Ferroptosis |
| A ferroptosis inducer. | ||
| M45075 | Ferroptocide | Ferroptosis |
| Ferroptocide is a small molecule inhibitor of thioredoxin, as well as an inducer of ferroptosis, with antitumor activity. | ||
| M13544 | Ammonium iron(III) citrate | Ferroptosis |
| Ammonium ferric citrate; FAC | ||
| Ammonium iron(III) citrate (Ammonium ferric citrate), a physiological form of nonetransferrin-bound iron, induces intracellular iron overload to cause ferroptosis. Ammonium iron(III) citrate can enhance protein production. | ||
| M21708 | Erastin2 | Ferroptosis |
| Erastin2 is a ferroptosis inducer and a potent, selective inhibitor of the system xc(-) cystine/glutamate transporter. | ||
| M27956 | EPI-743 | Mitochondrial Related |
| α-Tocotrienol quinone; PTC-743; Vatiquinone; NCT04378075 | ||
| EPI-743 (Vatiquinone; α-Tocotrienol quinone; PTC-743; NCT04378075) is a potent cellular oxidative stress protectant, inhibits ferroptosis in cells, which could be used for the study for mitochondrial diseases. EPI-743 is a synthetic analog of vitamin E with oral activity, targets repletion of reduced intracellular glutathione. | ||
| M29297 | PKUMDL-LC-101-D04 | Glutathione Peroxidase |
| GPX4-Activator-1d4 | ||
| PKUMDL-LC-101-D04 (GPX4-Activator-1d4) is a potent ferroptosis regulator glutathione peroxidase 4 (GPX4) allosteric activator (pEC50=4.7). PKUMDL-LC-101-D04 increases GPX4 activity to 150% at 20 μM in the cell-free assay and 61 μM in cell extracts. | ||
| M29325 | BODIPY 581/591 C11 | Fluorescent Dye |
| BODIPY 581/591 C11 is a BODIPY borofluoroprene derivative with good light stability and low fluorescence artifacts. BODIPY 581/591 C11 can be used for study lipid peroxidation and antioxidant properties in living cells, or detect ferroptosis by reaction with hydroxyl radicals. BODIPY 581/591 C11 is emitted at 591 nm (reduced prototype), or redshifted to 510 nm (oxidized type). The excitation wavelengths were 581 nm (reduced prototype) and 500 nm (oxidized type). | ||
| M39011 | W1131 | STAT |
| W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU. W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3 pathway and ferroptosis pathway. | ||
| M41344 | Lepadin E | Glutathione Peroxidase |
| Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. | ||
| M41345 | Moracin N | Glutathione Peroxidase |
| Moracin N is a ferroptosis inhibitor that can be isolated from mulberry leaf. | ||
| M42428 | NC-R17 | Glutathione Peroxidase |
| NC-R17 is a RSL3-based noncovalent GPX4 degrader, involving in Ferroptosis. | ||
| M43194 | Cathepsin B | Enzymes & Coenzymes |
| Cathepsin B is a cysteine protease and is involved in multiple kinds of programmed cell death (including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death). | ||
| M43932 | N6F11 | Ferroptosis |
| 2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one | ||
| N6F11 is a novel ferroptosis inducer that selectively triggers the ubiquitination degradation of GPX4 by binding to the specific structural domain of TRIM25, a ubiquitinated E3 ligase, which is expressed in tumor cells, leading to ferroptosis in cancer cells. | ||
| M45069 | Piperazine Erastin | Ferroptosis |
| Piperazine Erastin is an Erastin derivative and an inducer of ferroptosis. Piperazine erastin induces an iron-dependent form of non-apoptotic cell death. | ||
| M45392 | MMRi62 | Ferroptosis |
| MMRi62 is a ferroptosis inducer targeting MDM2-MDM4 (negative regulator of the oncogene p53), which induces ferroptosis accompanied by an increase in reactive oxygen species (ROS) and lysosomal degradation of ferritin heavy chain (FTH1).MMRi62 displays p53-independent apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells. MMRi62 shows p53-independent pro-apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells.) In addition, MMRi62 caused proteasomal degradation of mutant p53 and was active in vivo in an in situ xenograft PDAC mouse model characterized by high-frequency mutations in KRAS and TP53. | ||
| M45393 | YL-939 | Ferroptosis |
| YL-939 is a potent ferroptosis inhibitor that inhibits iron death by targeting the PHB2/ferritin/iron axis. | ||
| M49462 | GPX4-IN-3 | Ferroptosis |
| GPX4-IN-3 is a potent glutathione peroxidase 4 (GPX4) inhibitor that selectively induces ferroptosis.1 μM of GPX4-IN-3 inhibited 71.7% of GPX4 activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
